Beta Bionics (NASDAQ:BBNX) Insider Mike Mensinger Sells 2,650 Shares

Beta Bionics, Inc. (NASDAQ:BBNX) insider Mike Mensinger sold 2,650 shares of the company’s stock in a transaction dated Wednesday, September 16th. The stock was sold at an average price of $22.00, for a total transaction of $58,300.00. Following the completion of the sale, the insider owned 177,390 shares in the company, valued at $3,902,580. This represents a 1.47% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Mike Mensinger also recently made the following trade(s):

• On Wednesday, September 2nd, Mike Mensinger sold 4,375 shares of Beta Bionics stock. The shares were sold at an average price of $19.11, for a total transaction of $83,606.25.

Beta Bionics Stock Performance

BBNX stock opened at $21.43 on Friday. The company has a market capitalization of $964.14 million, a P/E ratio of -12.99 and a beta of 3.37. Beta Bionics, Inc. has a 52-week low of $8.80 and a 52-week high of $32.71. The business has a 50-day simple moving average of $17.56 and a two-hundred day simple moving average of $13.99.

Beta Bionics (NASDAQ:BBNX) last issued its quarterly earnings data on Wednesday, July 29th. The company reported ($0.53) EPS for the quarter, topping the consensus estimate of ($0.62) by $0.09. Beta Bionics had a negative return on equity of 26.30% and a negative net margin of 61.31%.The firm had revenue of $32.01 million during the quarter. As a group, sell-side analysts forecast that Beta Bionics, Inc. will post -2.05 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the business. Squarepoint Ops LLC purchased a new position in Beta Bionics in the second quarter valued at about $2,524,000. Bank of America Corp DE purchased a new stake in shares of Beta Bionics during the 2nd quarter worth approximately $8,566,000. Man Group plc purchased a new stake in shares of Beta Bionics during the 2nd quarter worth approximately $419,000. Legal & General Group Plc bought a new stake in shares of Beta Bionics in the 2nd quarter worth approximately $62,000. Finally, The Manufacturers Life Insurance Company bought a new stake in shares of Beta Bionics in the 2nd quarter worth approximately $172,000.

More Beta Bionics News

Here are the key news stories impacting Beta Bionics this week:

• Positive Sentiment: The FDA cleared Beta Bionics’ Mint patch pump, expanding its diabetes-device portfolio beyond the iLet Bionic Pancreas. A full U.S. launch is planned for the first quarter of 2027, creating a potential second growth engine. Beta Bionics Stock Surges on FDA Clearance for Mint Patch Pump
• Positive Sentiment: The company completed a public offering that raised $172.5 million in gross proceeds, including the underwriters’ full option exercise. The funds should support Mint commercialization, manufacturing, research and development, and working capital. Beta Bionics Announces Closing of $172.5 Million Public Offering
• Positive Sentiment: Analyst sentiment remains generally favorable, with several firms raising price targets; the reported consensus rating is “Moderate Buy,” supported by optimism about Mint and the company’s longer-term growth prospects.
• Neutral Sentiment: Insiders Mark Hopman and Mike Mensinger sold shares under pre-arranged Rule 10b5-1 plans. Hopman sold 30,779 shares for approximately $619,581, while Mensinger sold 2,650 shares for $58,300. Planned transactions do not necessarily signal a change in management’s outlook, but they may weigh on investor sentiment. Beta Bionics Insider Sells Stock
• Negative Sentiment: The equity raise included millions of newly issued shares and pre-funded warrants priced at $17.25, creating meaningful dilution for existing shareholders and contributing to near-term selling pressure.
• Negative Sentiment: Beta Bionics faces a securities class action alleging inadequate disclosures involving an FDA Form 483, a subsequent warning letter, quality-management and patient-safety issues, and unreported customer complaints. The allegations remain unproven, but the litigation adds regulatory, reputational and financial uncertainty. The lead-plaintiff deadline is November 3, 2026. BBNX Shareholder Alert
• Negative Sentiment: Fiscal 2026 revenue guidance of $121 million to $126 million is below the approximately $133.9 million analyst consensus, indicating weaker near-term growth expectations.

Analysts Set New Price Targets

BBNX has been the topic of several recent analyst reports. Truist Financial restated a “buy” rating and set a $23.00 price objective (up from $22.00) on shares of Beta Bionics in a research note on Tuesday. Weiss Ratings upgraded shares of Beta Bionics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Tuesday, August 18th. Robert W. Baird increased their target price on shares of Beta Bionics from $14.00 to $16.00 and gave the company a “neutral” rating in a report on Tuesday. William Blair began coverage on shares of Beta Bionics in a research report on Friday, August 21st. They set a “market perform” rating on the stock. Finally, The Goldman Sachs Group boosted their price target on shares of Beta Bionics from $17.00 to $19.00 and gave the stock a “buy” rating in a report on Wednesday, July 15th. Seven analysts have rated the stock with a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $21.90.

About Beta Bionics

Beta Bionics, Inc is a medical technology company focused on developing automated insulin-delivery systems for people with diabetes. Its principal product is the iLet Bionic Pancreas, an automated insulin-delivery system designed to simplify diabetes management by using continuous glucose monitoring data to adjust insulin dosing with limited user input.

The iLet Bionic Pancreas received clearance from the U.S. Food and Drug Administration in 2023 for use by people with type 1 diabetes.